Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERR-PA
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
ERR-PA is a small-molecule inhibitor of Estrogen-Related Receptor α (ERRα). It is being investigated for its potential in treating nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Studies have shown that ERR-PA blocks NAFLD development induced by high-carbohydrate or high-fat diets, diminishes lipid accumulation, and attenuates NASH development in Pten null mice. Its mechanism involves inhibiting ERRα, which is a major transcriptional regulator of lipid biosynthesis and mitochondrial function, and it has been identified to regulate glycerolipid synthesis with glycerophosphate acyltransferase 4 as a novel transcriptional target of ERRα.
02
Targets
ESRRA (Estrogen-related receptor alpha)
Beyond the preview
Go deeper on ERR-PA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERR-PA.